Youth and hormone receptors in breast cancer: Good or bad news first?

Lancet

Volumn 355, Issue 9218, 2000, Pages 1839-1840

  Stockler, Martin ^a   Beith, Jane ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; TAMOXIFEN;

ADULT; AGE; BREAST CANCER; CANCER SURVIVAL; FEMALE; HUMAN; MENOPAUSE; NOTE; OVARIECTOMY; PRIORITY JOURNAL;

EID: 0034720507     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02281-9     Document Type: Note

References (9)

1. Kroman N., Jensen M.-B., Wohlfahrt J., Mouridsen H.T., Andersen P.K., Melbye M. Factors influencing the effect of age on prognosis in breast cancer. population based study BMJ. 320:2000;474-479.
2. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 352:1998;930-942.
3. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 351:1998;1451-1467.
4. Ovarian ablation in early breast cancer: overview of the randomised trials. Lancet. 348:1996;1451-1467.
5. Barley V. Time for reappraisal of ovarian ablation in early breast cancer. Lancet. 348:1996;1184.
6. Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: the Scottish Trial. Lancet. 341:1993;1293-1298.
7. Ejlertsen B., Dombernowsky P., Mouridsen H.T.et al. Comparable effect of ovarian ablation (OA) and CMF chemotherapy in premenopausal hormone receptor positive breast cancer patients (PRP). Proc Am Soc Clin Oncol. 18:1999;248. Abstract.
8. Jakesz R., Hausmaninger H., Samonigg H.et al. Comparison of adjuvant therapy with tamoxifen and goserelin Vs. CMF in premenopausal stage I and II hormone-responsive breast cancer patients: four year results of Austrian Breast Cancer Study Group (ABCSG) Trial 5. Proc Am Soc Clin Oncol. 18:1999;250. Abstract.
9. Davidson N., O'Neill A., Vukov A.et al. Effect of chemohormonal therapy in premenopausal, node (+), receptor (+) breast cancer: an Eastern Cooperative Oncology Group Phase III Intergroup Trial (E5188, INT-0101). Proc Am Soc Clin Oncol. 18:1999;249. Abstract.